{"denoms":[{"counts":[{"groupId":"BG000","value":"52"}],"units":"Participants"}],"groups":[{"description":"Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles","id":"BG000","title":"Sorafenib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"26","upperLimit":"85","value":"62"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":">=65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"title":"< 65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"34"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"}]}],"title":"Adenocarcinoma NSCLC"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Large cell carcinoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Squamous cell (epidermoid) carcinoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Undifferentiated carcinoma"}],"description":"Measurable, histologically or cytologically documented stage IV non-small cell lung cancer (NSCLC). Subjects must have had disease progression at the time of study entry and have been treated with at least 1 but no more than 2 prior systemic agents or regimens (including gefitinib).","paramType":"NUMBER","title":"Histology","unitOfMeasure":"participants"}]}